Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France
- 7 July 2009
- journal article
- viral hepatitis
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 50 (5), 1351-1359
- https://doi.org/10.1002/hep.23159
Abstract
Clinicians continue to raise questions concerning the necessity of treating chronic hepatitis C virus (HCV)‐infected patients with normal alanine aminotransferase (N‐ALT), in light of their slower progression to cirrhosis than patients with elevated alanine aminotraferase (E‐ALT). This study was undertaken to predict the impact of pegylated interferon (IFN) and ribavirin on HCV‐related morbidity and mortality in patients with N‐ALT. A previous Markov model was adapted to separately simulate patients with N‐ALT (30%) and those with E‐ALT (70%). The model estimates fibrosis progression rates according to age, sex, and whether ALT levels are normal or elevated, assuming that patients with E‐ALT have a 2.6 times higher progression than those with N‐ALT. It takes into account improvement in HCV screening and treatment and competitive mortality. We assumed that N‐ALT patients were treated 80% less frequently between 2002 and 2004 and 70% less frequently from 2005 on, as obtained in real life from three multicentric cohorts (Hepatys, Adequation, Persee). Antiviral treatment of HCV‐infected populations might reduce 2008‐2025 HCV‐related morbidity and mortality by 34,200 cases of cirrhosis (36%, 33,000‐35,000), 22,400 complications (28%, 21,000‐23,000) and 17,500 deaths (25%, 17,000‐18,000), including 3000 cases of cirrhosis (22%, 2000‐5000), 1200 complications (15%, 1000‐1700), and 1000 deaths (14%, 900‐1300) in the N‐ALT population, despite a probability of receiving treatment that is three to five times less in this population. If N‐ALT patients are treated at the same proportions as those with E‐ALT, morbidity and mortality could be further reduced by 1400 cases of cirrhosis (13%, 1200‐2200), 600 complications (9%, 600‐1000), and 500 deaths (9%, 500‐800). Conclusion: Treatment of N‐ALT patients would decrease HCV morbidity and mortality. These patients should be considered candidates for treatment just as others are. (HEPATOLOGY 2009.)Keywords
This publication has 32 references indexed in Scilit:
- Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levelsJournal of Hepatology, 2009
- Natural history of initially mild chronic hepatitis CDigestive and Liver Disease, 2004
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- 606 Impaired quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levelsHepatology, 2003
- Prospective study on anti-hepatitis C virus–positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNAHepatology, 2001
- The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infectionGut, 2001
- Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity?European Journal of Gastroenterology & Hepatology, 2001
- Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis CHepatology, 1998
- Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activityHepatology, 1998
- Volunteer Blood Donors with Antibody to Hepatitis C Virus: Clinical, Biochemical, Virologic, and Histologic FeaturesAnnals of Internal Medicine, 1995